Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adaptive Therapy With Capecitabine in Metastatic ER+ Breast Cancer
NCT06525766Phase 2Recruiting
- Sponsor
- Mayo Clinic
- Start
- Oct 2025
- Primary completion
- Oct 2030
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine in breast cancer, sponsored by Mayo Clinic. Primary endpoint: Ability to achieve adaptive therapy (AT) up to 5 years. Started Oct 2025; status: recruiting.
02
Drugs
capecitabine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06525766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06525766.